Antibody–drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs)
covalently attached to a cytotoxic drug via a chemical linker. It combines both the …

Folate receptor α (FRα) came into focus as an anticancer target many decades after the
successful development of drugs targeting intracellular folate metabolism, such as …

Background Mirvetuximab soravtansine-gynx (MIRV), a first-in-class antibody–drug
conjugate targeting folate receptor α (FRα), is approved for the treatment of platinum …

Antibody–drug conjugates (ADCs) are a relatively new class of anticancer agents designed
to merge the selectivity of monoclonal antibodies with cell killing properties of …

Background Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate comprising a
folate receptor alpha (FRα)-binding antibody, cleavable linker, and the maytansinoid DM4, a …

PURPOSE This phase III, multicenter, randomized, open-label study investigated the
efficacy and safety of nivolumab versus chemotherapy (gemcitabine [GEM] or pegylated …

Ovarian cancer (OC) remains a fatal malignancy because most patients experience
recurrent disease, which is resistant to chemotherapy. The outcomes for patients with …

Background Survival rates for ovarian cancer remain poor, and monitoring and prediction of
therapeutic response may benefit from additional markers. Ovarian cancers frequently …

Poor tissue penetration remains a major challenge for antibody-based therapeutics of solid
tumors, but proper dosing can improve the tissue penetration and thus therapeutic efficacy of …

Novel biomarkers are needed to direct new treatments for ovarian cancer, a disease for
which the standard of care remains heavily focused on platinum-based chemotherapy …